MELBOURNE, Australia, June 5, 2025 /PRNewswire/ -- Global leading CFD broker KCM Trade announced an annual strategic partnership with Australian professional golfer Enshan Hooi, becoming an official sponsor for his 2025 golf tour. The signing ceremony was held at Enshan's training ground — the Medway Golf Club in Melbourne — where Enshan and Ryan, CEO of KCM Group officially signed the agreement in the presence of many golf enthusiasts.
This partnership continues KCM Trade's sports marketing strategy of "precisely targeting high-net-worth scenarios," marking a strategic upgrade from professional drifting events to the golf sector. With "professionalism, precision, and efficiency" at its core, the collaboration aims to build a value co-creation ecosystem between sport and finance.
Commitment to Professionalism: The Bond Between Enshan and KCM Trade
Building on his success as a multiple-time amateur tournament champion, he earned his place on the professional tour in 2024, marking his official entry into the professional golfing arena.
Enshan commented: "As a professional athlete, I choose to partner with professional companies. KCM Trade is a brand I have long been familiar with in Australia. Their foresight and strong commitment to supporting sporting events and nurturing young talent not only empower athletes to reach their potential but also make the journey towards their dreams full of confidence."
Strategy and Focus: A Two-Way Inspiration Between Golf and Finance
KCM Trade firmly believes that true brand influence stems from walking alongside those who share the same values. Jason Lau, Managing Director of KCM Trade Australia stated: "Golf and finance share common traits — strategy and focus. Golfers must control the power and angle of every shot through careful planning and a calm mindset, just as success in financial markets requires professional knowledge, meticulous planning, and adaptability."
"This partnership is more than just a sponsorship — it reflects the Group's commitment to nurturing talent. As KCM Trade's Chief Market Analyst, I often visit universities with my team to share knowledge and help develop the next generation's skills. We deeply understand the importance of cultivating new talent — every one of them, like Enshan, deserves their own stage," added Tim Waterer, KCM Trade's Chief Market Analyst and Forbes Advisor Australia Advisory Board Member.
Whether it's about mastering each stroke on the golf course or analysing every fluctuation in the financial markets, success is built on a keen eye for detail and relentless pursuit of improvement. KCM Trade believes it is precisely this focus on precision, control, and small adjustments that makes every breakthrough possible.
Website: https://www.kcmtrade.com/
---END---
About KCM Trade
Founded in 2016, KCM Trade is dedicated to offering reliable, customised, and efficient trading services, connecting clients to top global financial markets. As a liquidity provider, we support institutional clients through a global network and offer diverse trading options to retail clients. Our operations span Australia, Hong Kong SAR, Taipei City, Thailand, Malaysia, Vietnam, Mauritius, and other regions. With our experienced and professional team, we can provide all-rounded and reliable support for client transactions. KCM Trade is part of the KCM Group, affiliated companies include KCM Group Holdings Limited, Kohle Capital Markets Pty Ltd, and Kohle Capital Markets Ltd.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
KCM Trade Sponsors of Australian Golf Rising Star Enshan Hooi | Professional Tournament 2025
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
